KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Amortization of Deferred Charges: 2009-2020

Historic Amortization of Deferred Charges for Jazz Pharmaceuticals (JAZZ) over the last 12 years, with Dec 2020 value amounting to $56.7 million.

  • Jazz Pharmaceuticals' Amortization of Deferred Charges rose 30.73% to $15.7 million in Q1 2021 from the same period last year, while for Mar 2021 it was $60.3 million, marking a year-over-year increase of 27.68%. This contributed to the annual value of $56.7 million for FY2020, which is 22.12% up from last year.
  • Per Jazz Pharmaceuticals' latest filing, its Amortization of Deferred Charges stood at $56.7 million for FY2020, which was up 22.12% from $46.4 million recorded in FY2019.
  • Jazz Pharmaceuticals' Amortization of Deferred Charges' 5-year high stood at $56.7 million during FY2020, with a 5-year trough of $22.1 million in FY2016.
  • Over the past 3 years, Jazz Pharmaceuticals' median Amortization of Deferred Charges value was $46.4 million (recorded in 2019), while the average stood at $49.0 million.
  • Per our database at Business Quant, Jazz Pharmaceuticals' Amortization of Deferred Charges declined by 2.66% in 2016 and then soared by 46.41% in 2018.
  • Over the past 5 years, Jazz Pharmaceuticals' Amortization of Deferred Charges (Yearly) stood at $22.1 million in 2016, then surged by 35.66% to $30.0 million in 2017, then surged by 46.41% to $44.0 million in 2018, then climbed by 5.54% to $46.4 million in 2019, then rose by 22.12% to $56.7 million in 2020.